title: C60 fullerene as synergistic agent in tumor-inhibitory Doxorubicin treatment.
abstract: BACKGROUND
  Doxorubicin (Dox) is one of the most potent anticancer drugs, but its successful use is hampered by high toxicity caused mainly by generation of reactive oxygen species. One approach to protect against Dox-dependent chemical insult is combined use of the cytostatic drug with antioxidants. C60 fullerene has a nanostructure with both antioxidant and antitumor potential and may be useful in modulating cell responses to Dox.
  
  
  OBJECTIVE
  The aim of this study was to estimate the antitumor effect and antioxidant enzyme activity of combined C60 fullerene and Dox (C60 + Dox) in the liver and heart of mice with Lewis lung carcinoma compared with Dox treatment alone.
  
  
  METHODS
  Highly stable pristine C60 fullerene aqueous colloid solution (concentration 1.0 mg/ml, average hydrodynamic diameter of nanoparticles 50 nm) was used in the study and characterized by means of atomic force microscopy (AFM). The in vivo investigation of C60-Dox action was performed via the standard methods of histological and enzyme activity analyses.
  
  
  RESULTS
  Dox (total dose 2.5 mg/kg) combined with C60 fullerene (total dose 25 mg/kg) in tumor-bearing animals resulted in tumor growth inhibition, prolongation of life, metastasis inhibition, and increased number of apoptotic tumor cells and was more effective than the corresponding course of Dox treatment alone. C60 fullerene demonstrated a protective effect against superoxide dismutase and glutathione peroxidase inhibition induced by Dox-dependent oxidative insult in the liver and heart.
  
  
  CONCLUSIONS
  Combined treatment with C60 + Dox is considered to be a promising approach for cancer chemotherapy.
authors.affiliation: Joint Ukrainian-German Center on Nanobiotechnology, Kyiv, Ukraine.
authors.forename: Svitlana
authors.initials: S
authors.lastname: Prylutska
authors.forename: Iryna
authors.initials: I
authors.lastname: Grynyuk
authors.forename: Olga
authors.initials: O
authors.lastname: Matyshevska
authors.forename: Yuriy
authors.initials: Y
authors.lastname: Prylutskyy
authors.forename: Maxim
authors.initials: M
authors.lastname: Evstigneev
authors.forename: Peter
authors.initials: P
authors.lastname: Scharff
authors.forename: Uwe
authors.initials: U
authors.lastname: Ritter
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000473:pathology; D003102:Colloids / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D037741:Fullerenes / Q000008:administration & dosage / Q000627:therapeutic use*; D005979:Glutathione Peroxidase / Q000187:drug effects / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D009206:Myocardium / Q000201:enzymology; D053758:Nanoparticles / Q000008:administration & dosage; D013482:Superoxide Dismutase / Q000187:drug effects / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D003102:Colloids; D037741:Fullerenes; D004317:Doxorubicin; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; C069837:fullerene C60